Advertisement

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement

Nov

14

Today In Oncology

Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer

FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

American Cancer Society Updates Prostate Cancer Screening Guideline

Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer

Advertisement

© 2026 HSP News Service, L.L.C.